Abstract:Background. Diabetic kidney disease (DKD), one of the most common causes of end-stage renal disease (ESRD), remains prevalent in many populations. Podocyte loss and apoptosis play a crucial role in the progression of DKD. Tripterygium glycoside (TG), a widely used Chinese herb, exerted comprehensive protective effects on preventing DKD progression. This study was performed to assess the podocyte protective effect of tripterygium glycoside on DKD by the potential role of activation of autophagy and downregulating beta-arrestin-1. Methods. Tripterygium glycoside and small interfering RNA (siRNA) of beta-arrestin-1 were added to 10% db/db mice high-glucose serum induced podocytes in vitro. Autophagic activity was evaluated by transmission electronic microscopy, immunofluorescence staining and western blot analysis. Apoptotic activity was evaluated by Annexin V-FITC/PI flow cytometric analysis. The levels of nephrin and podocin, a marker protein of podocytes, were examined using western blot analysis. Results. Significantly ameliorated podocyte apoptosis, increased nephrin and podocin levels and inhibited expression of beta-arrestin-1 were observed after pretreatment of tripterygium glycoside in DKD mouse serum treated podocytes. Significantly higher levels of autophagic activity were also observed. Silencing beta-arrestin-1 upregulated autophagic activity and ameliorated podocyte apoptosis. Silencing beta-arrestin-1 in combination with tripterygium glycoside enhanced the levels of LC3-II and LC3-II/LC3-I ratios and reduced the expression of p62. Finally, we observed a notable reduction in podocyte apoptotic rate in DKD serum + siRNA-beta-arrestin-1 + TG group compared to DKD serum + siRNA-beta-arrestin-1 group, and upregulated protein levels of nephrin and podocin compared to treatment with siRNA-beta-arrestin-1 only. Conclusions. This study demonstrated that tripterygium glycoside provided protection against podocyte injury induced by high-glucose serum, and that this effect was mediated by the concomitant activation of autophagy and downregulation of beta-arrestin-1.

CHILKBP protects against podocyte injury by preserving ZO-1 expression

Krppel‑like Factor4 Ameliorates Diabetic Kidney Disease by Activating Autophagy Via the Mtor Pathway

Tripterygium glycoside protects diabetic kidney disease mouse serum-induced podocyte injury by upregulating autophagy and downregulating β-arrestin-1.

Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models.

Inhibiting calpain 1 and 2 in cyclin G associated kinase–knockout mice mitigates podocyte injury

Down-regulation of Integrin Β1 and Focal Adhesion Kinase in Renal Glomeruli under Various Hemodynamic Conditions.

Calcineurin Inhibitors Ameliorate PAN‐induced Podocyte Injury Through the NFAT–Angptl4 Pathway

Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy

Podocyte‐related Proteins in Membranous Nephropathy Progression

KIBRA upregulation increases susceptibility to podocyte injury and glomerular disease progression

Profilin1 is required for prevention of mitotic catastrophe in murine and human glomerular diseases

Podocyte Autophagic Activity Plays a Protective Role in Renal Injury and Delays the Progression of Podocytopathies.

[New Insight in Pathogenesis of Podocyte Disfunction in Minimal Change Disease].

Plakoglobin is involved in cytoskeletal rearrangement of podocytes under the regulation of UCH-L1.

Podocyte-specific deletion of ubiquitin carboxyl-terminal hydrolase L1 causes podocyte injury by inducing endoplasmic reticulum stress.

DACH1 Protects Podocytes from Experimental Diabetic Injury and Modulates PTIP-H3K4Me3 Activity

TYRO3 Protects Podocyte Via JNK/c-jun-P53 Pathway.

Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease

Dissection of Glomerular Transcriptional Profile in Patients with Diabetic Nephropathy: SRGAP2a Protects Podocyte Structure and Function.

Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease

Protein phosphatase 2A modulates podocyte maturation and glomerular functional integrity in mice